4//SEC Filing
SVLSF IV, LLC 4
Accession 0000899243-19-010492
CIK 0001348911other
Filed
Apr 9, 8:00 PM ET
Accepted
Apr 10, 7:21 PM ET
Size
21.2 KB
Accession
0000899243-19-010492
Insider Transaction Report
Form 4
SVLSF IV, LLC
10% Owner
Transactions
- Sale
Common Stock
2019-04-10$29.40/sh−374$10,994→ 47,471 total - Sale
Common Stock
2019-04-09$28.53/sh−13,292$379,227→ 1,685,262 total - Sale
Common Stock
2019-04-08$29.49/sh−629$18,550→ 48,222 total - Sale
Common Stock
2019-04-09$28.53/sh−377$10,756→ 47,845 total - Sale
Common Stock
2019-04-08$29.49/sh−22,171$653,865→ 1,698,554 total - Sale
Common Stock
2019-04-10$29.40/sh−13,157$386,753→ 1,672,105 total
Transactions
- Sale
Common Stock
2019-04-09$28.53/sh−13,292$379,227→ 1,685,262 total - Sale
Common Stock
2019-04-09$28.53/sh−377$10,756→ 47,845 total - Sale
Common Stock
2019-04-10$29.40/sh−374$10,994→ 47,471 total - Sale
Common Stock
2019-04-08$29.49/sh−22,171$653,865→ 1,698,554 total - Sale
Common Stock
2019-04-08$29.49/sh−629$18,550→ 48,222 total - Sale
Common Stock
2019-04-10$29.40/sh−13,157$386,753→ 1,672,105 total
SV Life Sciences Fund IV (GP), L.P.
10% Owner
Transactions
- Sale
Common Stock
2019-04-08$29.49/sh−629$18,550→ 48,222 total - Sale
Common Stock
2019-04-09$28.53/sh−13,292$379,227→ 1,685,262 total - Sale
Common Stock
2019-04-09$28.53/sh−377$10,756→ 47,845 total - Sale
Common Stock
2019-04-10$29.40/sh−374$10,994→ 47,471 total - Sale
Common Stock
2019-04-08$29.49/sh−22,171$653,865→ 1,698,554 total - Sale
Common Stock
2019-04-10$29.40/sh−13,157$386,753→ 1,672,105 total
SV LIFE SCIENCES FUND IV LP
10% Owner
Transactions
- Sale
Common Stock
2019-04-08$29.49/sh−22,171$653,865→ 1,698,554 total - Sale
Common Stock
2019-04-08$29.49/sh−629$18,550→ 48,222 total - Sale
Common Stock
2019-04-10$29.40/sh−374$10,994→ 47,471 total - Sale
Common Stock
2019-04-09$28.53/sh−377$10,756→ 47,845 total - Sale
Common Stock
2019-04-09$28.53/sh−13,292$379,227→ 1,685,262 total - Sale
Common Stock
2019-04-10$29.40/sh−13,157$386,753→ 1,672,105 total
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.13 to $30.08, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]These shares are held directly by SVLS IV LP.
- [F3]SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein.
- [F4]These shares are held directly by Strategic Partners.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.02 to $29.685, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.07 to $29.71, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
KalVista Pharmaceuticals, Inc.
CIK 0001348911
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001422339
Filing Metadata
- Form type
- 4
- Filed
- Apr 9, 8:00 PM ET
- Accepted
- Apr 10, 7:21 PM ET
- Size
- 21.2 KB